OPTOCEUTICS APS

Their core work

Optoceutics is a Danish neurotechnology SME developing light-based therapies for neurological diseases, most notably using 40 Hz flickering light stimulation to slow Alzheimer's Disease progression — a technique grounded in gamma oscillation research. They also contribute specialist expertise in flexible electronics and advanced biomaterials for brain interfacing, as demonstrated through their participation in the ASTROTECH consortium studying astrocyte function. Their work sits at the intersection of photonics, neurostimulation hardware, and cellular neuroscience, making them an unusual combination of commercial product developer and deep-science contributor. They are technology builders, not just researchers — their earliest EU project was a commercialization feasibility study, not basic science.

What they specialise in

How they've shifted over time

In 2019, Optoceutics entered the EU funding landscape with a tightly scoped commercial idea — an SME Phase 1 feasibility study around a specific light-therapy product for Alzheimer's, with no published research keywords beyond the disease target. By 2020, they shifted into a five-year scientific research consortium (ASTROTECH, MSCA-ITN), contributing to fundamental neuroscience at the cellular level — astrocytes, biomaterials, flexible electronics, computational neuroscience. This progression suggests the company is deliberately strengthening its scientific foundations: they launched with a product concept and are now building the deeper mechanistic understanding and hardware expertise needed to validate and advance it.

Optoceutics is moving from applied product development toward foundational neuroscience and neural interface hardware — a trajectory that points toward more sophisticated brain-computer interface or closed-loop neurostimulation applications in the near future.

How they like to work

Optoceutics has taken both the coordinator role (BRIGHT, a lean SME feasibility study) and a participant role in a large research training network (ASTROTECH). This flexibility — leading when the goal is commercial validation, joining as a specialist when deep science is needed — is characteristic of agile deep-tech SMEs. With 10 partners across 6 countries from just two projects, they have a healthy European footprint for their size, and their MSCA-ITN involvement suggests they are comfortable operating inside academic-led consortia.

Optoceutics has built a network of 10 unique consortium partners spanning 6 European countries in just two projects, a solid reach for an SME of their size and age. Their ASTROTECH participation likely connects them to universities and research institutes across multiple EU member states working on neuroscience and neurotechnology.

What sets them apart

Optoceutics occupies a rare niche: they are a commercially oriented SME that combines a specific therapeutic modality (non-invasive light stimulation) with hands-on hardware expertise in flexible electronics and biomaterials for the brain — most players in this space are either pure-research labs or pure-device companies, not both. Their early Alzheimer's focus gives them a defined clinical application to anchor technology development, which makes them a credible partner for both clinical research consortia and neurotechnology hardware projects. For a consortium builder, they offer the SME commercial perspective alongside genuine deep-tech neuroscience capability — a combination that strengthens Horizon Europe proposals targeting health impact.

Highlights from their portfolio

• BRIGHT
  Coordinator role on an SME Phase 1 feasibility study commercializing 40 Hz masked light therapy for Alzheimer's Disease — a highly specific and commercially promising neuromodulation application.
• ASTROTECH
  Largest project by budget (€595K to Optoceutics alone) and a 5-year MSCA training network, signaling that Optoceutics is embedded in a serious academic neuroscience consortium studying the underexplored role of astrocytes in brain disease.